ABOUT - Scientific Advisory Board

Susumu Tonegawa, Ph.D.
Dr. Tonegawa, 1987 Nobel Prize winner in Medicine, is a professor at the Massachusetts Institute of Technology (MIT), director of the RIKEN-Picower-MIT Center for Neural Circuit Genetics, and a Howard Hughes Medical Institute Investigator. His expertise spans the fields of immunology and neuroscience. In the area of neuroscience, he has pioneered the use of genetically modified mice to understand the molecular basis of learning and memory. Recent advances in his laboratory include the development of a variety of animal models to study cognitive and psychiatric diseases. Dr. Tonegawa is a scientific founder of Galenea and provides specific expertise in molecular and behavioral neuroscience and mouse molecular genetic technology.

Magid Abou-Gharbia, Ph.D., FRCS
Dr. Abou-Gharbia is the Associate Dean for Research, Professor of Medicinal Chemistry and Director of the Moulder Center for Drug Discovery Research (MCDDR) at the School of Pharmacy, Temple University. Prior to joining Temple University in 2008, Dr. Abou-Gharbia spent 26 years at Wyeth Pharmaceuticals where he was Senior Vice President and Head of Chemical Screening Sciences. He was responsible for overseeing and directing the chemistry and screening research efforts of over 500 scientists at four U.S. research facilities and one in Hyderabad, India in support of drug discovery in neuroscience, inflammation, women's health/bone, oncology and cardiovascular disease. His research efforts resulted in 100 U.S. patents and over 350 worldwide patents and contributed to the discovery of several marketed drugs and many compounds currently under clinical evaluation including two SNRI anti-depressants, Effexor® and Pristiq®, an anticancer rapamycin derivative, Torisel®, a broad spectrum antibiotic, Tygacil®, and a selective estrogen receptor modulator, bazedoxifene. Dr. Abou-Gharbia received his Ph.D. in Organic Chemistry from the University of Pennsylvania. After a two year NIH Postdoctoral Fellowship at Temple University, he joined Wyeth. Dr. Abou-Gharbia will provide expertise and insight into strategies and medicinal chemistry approaches utilized in the design of novel small molecules CNS therapeutics.

Joseph A. Gogos, M.D., Ph.D.
Dr. Gogos is an assistant professor at Columbia University Center for Neurobiology and Behavior. He received an M.D. from the National University of Greece and a Ph.D. from Harvard University. Dr. Gogos is a leading authority on the genetic and biological basis of schizophrenia. His research is aimed at identifying genes that influence the processing of sensory information by the mammalian brain and the decoding of this information into specific behaviors. His work also focuses on understanding how sensory processing and integration is affected in psychiatric disease states and elucidating the genetic basis of these deficits. A major goal of his research is to gain understanding of the biological function of schizophrenia susceptibility elements through analysis at the cellular, physiological and behavioral levels. Dr. Gogos provides unique insight on the mechanistic basis of schizophrenia and related psychiatric disorders.

Karoly Nikolich, Ph.D.
Dr. Nikolich is Consulting Professor at Stanford University Medical School in the Departments of Psychiatry and Behavioral Sciences, as well as advisor and board member of pharmaceutical and biotechnology companies and investment funds. He is also CEO of Amnestix, Inc, the US subsidiary of SYGNIS Pharma AG. During his three decades of life sciences, biotechnology and pharmaceutical experience, Dr. Nikolich has built and led R&D departments spanning from discovery to human clinical development. Between 1983 and 1995, he worked as a scientist and head of neuroscience at Genentech, Inc. Subsequently, Dr. Nikolich was Vice President of Research at Lynx Therapeutics, the company that pioneered bead-based genomics. During this time, Dr. Nikolich was president of Lynx Europe and director of BASF-Lynx joint venture in Heidelberg, Germany. Later, Dr. Nikolich has started several biotechnology companies, including AGY Therapeutics, Neurofluidics, and Amnestix. He also led the Neuroscience Institute at Stanford University between 2005-2007 as executive director. Dr. Nikolich has served as advisor to several investment funds in the US, Europe and Asia. He is board or scientific advisory board member at Angiochem, Inc. a Canadian biotechnology company, Biovail, a US-Canadian pharmaceutical company, ExcelImmune, a US immunology company, and febit GmbH, a German genomics company.

Dr. Nikolich conducted his undergraduate and graduate studies in chemistry, biology and neurosciences at Eötvös University of Sciences in Budapest, Hungary. After his graduation in 1975, he joined the laboratory of Nobel Laureate Andrew V. Schally at Tulane University in New Orleans and later C.H. Li at the University of California San Francisco, in the United States, before joining Genentech.

Timothy A. Ryan, Ph.D.
Dr. Ryan is Professor of Biochemistry at Weill Cornell Medical College, a Rockefeller/Sloan-Kettering/Cornell Tri-Institutional Professor, a former Alfred P. Sloan Research Fellow and two-time winner of a McKnight Technological Innovations in Neuroscience Award. After obtaining a Ph.D. in Physics from Cornell, Dr. Ryan performed postdoctoral research in the Department of Molecular and Cellular Physiology at Stanford Medical School and joined the faculty at Weill Cornell in 1997. The primary focus of Dr. Ryan's research lies in understanding the regulation of synaptic vesicle trafficking in presynaptic terminals and how this process impacts presynaptic function. Dr. Ryan has published numerous scientific papers on this topic and has chaired several international scientific conferences.

Alain Stricker-Krongrad, Ph.D.
Dr. Stricker-Krongrad is Chief Scientific Officer and Senior Scientific Adviser at Charles River Laboratories. Dr. Stricker-Krongrad has managed pharmacokinetics, efficacy and safety departments for multiple disease indications within Charles River Laboratories, Millennium Pharmaceuticals in the U.S., and Novartis Headquarters and Ciba-Geigy in Switzerland. Dr. Stricker-Krongrad received his License, Master and Ph.D. degrees from the University of Nancy, France. He conducted his doctoral and post-doctoral research on preclinical and clinical drug evaluation at the National Institute of Scientific and Medical Research (INSERM) for which he has received two international awards for distinguished research. Dr. Stricker-Krongrad has received accreditations from the National List of Qualifications in both Pharmaceutical Sciences and Pharmacology (France), and is presently Adjunct Professor of Pharmacology at the Massachusetts College of Pharmacy. He is an elected Member of the American College of Clinical Pharmacology and a member of the American College of Toxicology. He plays an active role in the Safety Pharmacology Society and is on the Editorial Board of Expert Opinion in Drug Discovery. Dr. Stricker-Krongrad has published more than 60 peer-reviewed articles and brings a wealth of expertise in preclinical and early clinical drug efficacy and safety evaluation.